Original report| Volume 9, ISSUE 5, P449-456, May 2008

Download started.


Central Pituitary Adenylate Cyclase 1 Receptors Modulate Nociceptive Behaviors in Both Inflammatory and Neuropathic Pain States


      The pituitary adenylate cyclase–activating polypeptide type 1 receptor (PAC1-R) is a member of the 7-transmembrane domain, group 2 G-protein coupled receptor family. PAC1-Rs modulate neurotransmission and neurotrophic actions and have been implicated in both pronociception and antinociception. To better understand the role of PAC1-Rs in pain, PACAP 6-38, a PAC1-R antagonist, was evaluated in several inflammatory and neuropathic pain models after intrathecal (i.t.) administration. PACAP 6-38 potently reduced mechanical allodynia in a neuropathic spinal nerve ligation model (77% ± 15% maximal effect at 12 nmol, P < .01) and was also effective in reducing thermal hyperalgesia in the carrageenan model of inflammatory pain (89% ± 17% maximal effect at 12 nmol, P < .01). Although nociceptive responses were also attenuated with PACAP 6-38 in a dose-dependent manner in models of chronic inflammatory and persistent pain, no effects on motor performance were observed at analgesic doses. Taken together, these data demonstrate that blockade of the PAC1-R/PACAP complex by PACAP 6-38 can effectively attenuate thermal hyperalgesia and mechanical allodynia associated with inflammatory and neuropathic pain states. These results further emphasize that at the level of the spinal cord, PAC1-R activation is pronociceptive.


      This article presents the analgesic profile generated by the blockade, at the spinal cord level, of the PAC-1 receptor by a potent peptide antagonist. This comprehensive data set demonstrates that if small molecule PAC-1 receptor antagonists could be identified, they would potentially produce broad-spectrum analgesia in both inflammatory and neuropathic pain states.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The Journal of Pain
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Abbott F.V.
        • Franklin K.B.
        • Westbrook R.F.
        The formalin test: Scoring properties of the first and second phases of the pain response in rats.
        Pain. 1995; 60: 91-102
        • Arimura A.
        Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems.
        Jpn J Physiol. 1998; 48: 301-331
        • Bennett G.J.
        • Xie Y.K.
        A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man.
        Pain. 1988; 33: 87-107
        • Bockaert J.
        • Pin J.P.
        Molecular tinkering of G protein-coupled receptors: An evolutionary success.
        EMBO J. 1999; 18: 1723-1729
        • Bove S.E.
        • Calcaterra S.L.
        • Brooker R.M.
        • Huber C.M.
        • Guzman R.E.
        • Juneau P.L.
        • Schrier D.J.
        • Kilgore K.S.
        Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis.
        Osteoarth Cartil. 2003; 11: 821-830
        • Davis-Taber R.A.
        • Scott V.E.
        Transcriptional profiling of dorsal root ganglia in a neuropathic pain model using microarray and laser capture microdissection.
        Drug Dev Res. 2006; 67: 308-330
        • Dickinson T.
        • Fleetwood-Walker S.M.
        VIP and PACAP: Very important in pain?.
        TIPS. 1999; 20: 324-329
        • Dickinson T.
        • Mitchell R.
        • Robberecht P.
        • Fleetwood-Walker S.M.
        The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy.
        Neuropharmacology. 1999; 38: 167-180
        • Garry E.M.
        • Delaney A.
        • Blackburn-Munro G.
        • Dickinson T.
        • Moss A.
        • Nakalembe I.
        • Robertson D.C.
        • Rosie R.
        • Robberecht P.
        • Mitchell R.
        • Fleetwood-Walker S.M.
        Activation of p38 and p42/44 MAP kinase in neuropathic pain: Involvement of VPAC2 and NK2 receptors and mediation by spinal glia.
        Mol Cell Neurosci. 2005; 30: 523-537
        • Jongsma H.
        • Pettersson L.M.E.
        • Zhang Y.-Z.
        • Reimer M.K.
        • Kanje M.
        • Waldenstrom A.
        • Sundler F.
        • Danielsen N.
        Markedly reduced chronic nociceptive response in mice lacking the PAC1 receptor.
        NeuroReport. 2001; 12: 2215-2219
        • Jongsma Wallin H.
        • Pettersson L.M.
        • Verge V.M.
        • Danielsen N.
        Effect of anti-nerve growth factor treatment on pituitary adenylate cyclase activating polypeptide expression in adult sensory neurons exposed to adjuvant induced inflammation.
        Neuroscience. 2003; 120: 325-331
        • Kim S.H.
        • Chung J.M.
        An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat.
        Pain. 1992; 50: 355-363
        • Levine E.S.
        • Kolb J.E.
        Brain-derived neurotrophic factor increases activity of NR2B-containing N-methyl-D-aspartate receptors in excised patches from hippocampal neurons.
        J Neurosci Res. 2000; 62: 357-362
        • Lin S.Y.
        • Wu K.
        • Levine E.S.
        • Mount H.T.
        • Suen P.C.
        • Black I.B.
        BDNF acutely increases tyrosine phosphorylation of the NMDA receptor subunit 2B in cortical and hippocampal postsynaptic densities.
        Brain Res Mol Brain Res. 1998; 55: 20-27
        • Mabuchi T.
        • Shintani N.
        • Matsumura S.
        • Okuda-Ashitaka E.
        • Hashimoto H.
        • Muratani T.
        • Minami T.
        • Baba A.
        • Ito S.
        Pituitary adenylate cyclase-activating polypeptide is required for the development of spinal sensitization and induction of neuropathic pain.
        J Neurosci. 2004; 24: 9283-9291
        • Macdonald D.S.
        • Weerapura M.
        • Beazely M.A.
        • Martin L.
        • Czerwinski W.
        • Roder J.C.
        • Orser B.A.
        • MacDonald J.F.
        Modulation of NMDA receptors by pituitary adenylate cyclase activating peptide in CA1 neurons requires Gαq, protein kinase C, and activation of Src.
        J Neurosci. 2005; 25: 11374-11384
        • Macsai M.
        • Pataki I.
        • Toth G.
        • Szabo G.
        The effects of pituitary adenylate cyclase-activating polypeptide on acute and chronic morphine actions in mice.
        Regul Peptides. 2002; 109: 57-62
        • Martin M.
        • Otto C.
        • Santamarta M.T.
        • Torrecilla M.
        • Pineda J.
        • Schutz G.
        • Maldonaldo R.
        Morphine withdrawal is modified in pituitary adenylate cyclase-activating polypeptide type I-receptor-deficient mice.
        Mol Brain Res. 2003; 110: 109-118
        • McDougall J.J.
        • Watkins L.
        • Li Z.
        Vasoactive intestinal peptide (VIP) is a modulator of joint pain in a rat model of osteoarthritis.
        Pain. 2006; 123: 98-105
        • Merighi A.
        • Carmignoto G.
        • Gobbo S.
        • Lossi L.
        • Salio C.
        • Vergnano A.M.
        • Zonta M.
        Neurotrophins in spinal cord nociceptive pathways.
        Prog Brain Res. 2004; 146: 291-321
        • Miyata A.
        • Arimura A.
        • Dahl R.R.
        • Minamino N.
        • Uehara A.
        • Jiang L.
        • Culler M.D.
        • Coy D.H.
        Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells.
        Biochem Biophys Res Commun. 1989; 164: 567-574
        • Narita M.
        • Dun S.L.
        • Dun N.J.
        • Tseng L.F.
        Hyperalgesia induced by pituitary adenylate cyclase-activating polypeptide in the mouse spinal cord.
        Eur J Pharmacol. 1996; 311: 121-126
        • Ohsawa M.
        • Brailoiu G.C.
        • Shiraki M.
        • Dun N.J.
        • Paul K.
        • Tseng L.F.
        Modulation of nociceptive transmission by pituitary adenylate cyclase activating polypeptide in the spinal cord of the mouse.
        Pain. 2002; 100: 27-34
        • Pellegri G.
        • Magistretti P.J.
        • Martin J.-L.
        VIP and PACAP potentiate the action of glutamate on BDNF expression in mouse cortical neurons.
        Eur J Neurosci. 1998; 10: 272-280
        • Tams J.W.
        • Jorgensen R.M.
        • Holm A.
        • Fahrenkrug J.
        Creation of a selective antagonist and agonist of the rat VPAC1 receptor using a combinatorial approach with vasoactive intestinal peptide 6-23 as template.
        Mol Pharmacol. 2000; 58: 1035-1041
        • Vaudry D.
        • Gonzalez B.J.
        • Basille M.
        • Yon L.
        • Fournier A.
        • Vaudry H.
        Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.
        Pharmacol Rev. 2000; 52: 269-324
        • Xu X.-J.
        • Wiesenfeld-Hallin Z.
        Intrathecal pituitary adenylate cyclase activating polypeptide facilitates the spinal nociceptive flexor reflex in the rat.
        Neuroscience. 1996; 72: 801-804
        • Yaka R.
        • He D.-Y.
        • Phamluong K.
        • Ron D.
        Pituitary adenylate cyclase-activating polypeptide (PACAP(1-38)) enhances N-methyl-D-aspartate receptor function and brain-derived neurotrophic factor expression via RACK1*.
        J Biol Chem. 2003; 278: 9630-9638
        • Yaksh T.L.
        • Rudy T.A.
        Chronic catheterization of the spinal subarachnoid space.
        Physiol Behav. 1976; 17: 1031-1036
        • Yamamoto T.
        • Tatsuno I.
        Antinociceptive effect of intrathecally administered pituitary adenylate cyclase activating polypeptide (PACAP) on the rat formalin test.
        Neurosci Lett. 1995; 184: 32-35
        • Zhang Y.
        • Malmberg A.B.
        • Sjolund B.
        • Yaksh T.L.
        The effect of pituitary adenylate cyclase activating peptide (PACAP) on the nociceptive formalin test.
        Neurosci Lett. 1996; 207: 187-190
        • Zhang Y.Z.
        • Hannibal J.
        • Zhao Q.
        • Moller K.
        • Danielsen N.
        • Fahrenkrug J.
        • Sundler F.
        Pituitary adenylate cyclase activating peptide expression in the rat dorsal root ganglia: up-regulation after peripheral nerve injury.
        Neuroscience. 1996; 74: 1099-1110